Journal of Controlled Release, 329 (2021), 758-761.
Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated antiviral activity against a number of DNA and RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this paper, the authors discuss how novel formulations employing micro- and nanotechnologies may address concerns involving formulation change requirements.
The authors are concerned that Ivermectin should optimally be administered directly to the lungs, possibly via inhalation. They describe other formulations being used such as liposomes, and PLGA nanoparticles which can cross the intestinal epithelial barrier when given orally.
QUOTE: “In an optimistic scenario, new drug dosage forms may not only contribute to mitigate SARS-CoV-2 infection, but also be effective against other emerging viral diseases.”
NOTE: Table 1 lists a number of ongoing studies on Ivermectin.
